Reply to the Letter regarding “Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study”
Article information
Dear Editor,
In our recent retrospective study, we investigated the efficacy of ablation therapy in treating solitary hepatocellular carcinoma (HCC) with a diameter of ≤5 cm.1 Our findings suggest that ablation can be a viable alternative to surgery, particularly for cases where the HCC is no larger than 3 cm. When comparing the outcomes for HCCs measuring 3-5 cm, overall survival did not differ significantly between ablation and surgery. However, surgery demonstrated superior recurrence-free survival compared to ablation in this specific size range.
Dr. Kim, in a recent letter to the editor, emphasized the necessity for a well-designed randomized controlled study to comprehensively assess the effectiveness of ablation and surgery in treating solitary HCC of various sizes. Acknowledging the multitude of factors influencing treatment effectiveness, Dr. Kim pointed out the limitations of existing randomized controlled trials (RCTs) in providing detailed insights into the efficacy within specific populations.
We share Dr. Kim's perspective, particularly regarding the importance of an RCT focusing on the effectiveness of surgery and ablation for solitary HCC measuring 3-5 cm. While subgroup analyses of existing RCTs within Milan criteria did not reveal significant differences in overall survival or progression-free survival for solitary HCC measuring 3-5 cm,2 this information falls short in guiding precise treatment selection in specific scenarios. An in-depth analysis considering factors such as age, patient comorbidity, and tumor location is crucial.
A forthcoming large-scale RCT, with a specific focus on solitary HCC measuring 3-5 cm, should incorporate subgroup analyses that explore factors influencing treatment selection. Such analyses would provide valuable insights into optimal treatment choices based on individual patient backgrounds. Despite the need for further research, our study results suggest that clinicians, by considering patient backgrounds, have been adept at selecting appropriate treatments, as evidenced by the absence of significant differences in overall survival between ablation and surgery in our study.
Notes
Conflict of Interest
Kazuhiro Nouso is an editorial board member of Journal of Liver Cancer, and was not involved in the review process of this article. Otherwise, the authors have no conflicts of interest to disclose.
Ethics Statement
Not applicable.
Funding Statement
None.
Data Availability
Not applicable.
Author Contribution
Writing - original draft: KN
Writing - review & editing: KN, KK